DAXI 80 U
Phase 2Biologic
DAXI 80 U is one of 48 biologic programs targeting Plantar Fasciitis. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in Spasticity
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Namenda
AbbVieApproved
Cesamet
BBausch Health Americas, Inc.
Approved
Zanaflex
LLegacy Health System
Approved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Meditoxin
MMedy-Tox
Approved
Botox
AbbViePhase 3
Onabont-a
IpsenApproved
GSK1358820
GSKPhase 3
Sativex
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DAXI 80 U. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- RRevance Therapeutics, Inc.